MarketCap
Facebook
X
Telegram
Eiger BioPharmaceuticals Balance Sheet 2023-2011 | EIGR
Brief overview of Eiger BioPharmaceuticals's financial position
Balance sheet changes are traced across five available annual reports between 2019 and 2023.
Assets finished at $38.8 million versus $105.1 million initially, losing -63.1%. The balance sheet contracted.
Funding shifted toward liabilities: they gained +9.5%, compared with -63.1% for assets.
Net asset value fell below zero as liabilities exceeded assets. This is one of the most material balance sheet risks.
Cash accounts for 65.5% of assets versus 37.4% initially. The change indicates the degree of financial flexibility.
Retained earnings remain negative at -$512.2 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
What the balance sheet shows
Eiger BioPharmaceuticals has limited balance sheet resilience and depends heavily on cash generation and refinancing capacity.
Annual Balance Sheet Eiger BioPharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | 14.3 M | 2.39 M | 2.91 M | -8.45 M | -35.6 M | -16.9 M | -13 M | -27.3 M | 11 M | -6.86 M | -13.8 M | - |
Long Term Debt |
- | 39.6 M | 24 M | 31.2 M | 30.4 M | 25.6 M | 13.1 M | 14.7 M | - | 11.8 M | - | - | - |
Long Term Debt Current |
84 K | 491 K | 628 K | 582 K | 534 K | - | 2 M | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 31.9 M | 31.7 M | 25.8 M | 13.1 M | 14.7 M | 24 K | 298 K | 37 K | 10.3 M | - |
Total Current Liabilities |
53.3 M | 25.1 M | 29.9 M | 16.6 M | 16.9 M | 10 M | 7.27 M | 5.29 M | 8.39 M | 286 K | 6.56 M | - | - |
Total Liabilities |
53.3 M | 64.8 M | 54 M | 48.6 M | 48.7 M | 35.9 M | 20.4 M | 20 M | 10.7 M | 286 K | 12 M | 12.1 M | - |
Retained Earnings |
-512 M | -437 M | -340 M | -306 M | -241 M | -171 M | -119 M | -76.4 M | -29.3 M | -15.9 M | -113 M | -92.6 M | - |
Total Assets |
38.8 M | 120 M | 126 M | 144 M | 105 M | 102 M | 42.9 M | 60.7 M | 5.58 M | 816 K | 21.2 M | 35.9 M | - |
Cash and Cash Equivalents |
25.4 M | 25.8 M | 22.2 M | 28.9 M | 39.4 M | 61.3 M | 32 M | 27.8 M | 4.78 M | 777 K | 145 K | 253 K | - |
Book Value |
-14.5 M | 55.3 M | 72.4 M | 95 M | 56.5 M | 66.6 M | 22.5 M | 40.7 M | -5.15 M | 531 K | 9.11 M | 23.9 M | - |
Total Shareholders Equity |
-14.5 M | 55.3 M | 72.4 M | 95 M | 56.5 M | 66.6 M | 22.5 M | 40.7 M | -5.15 M | 531 K | 105 K | 248 K | - |
All numbers in USD currency
Quarterly Balance Sheet Eiger BioPharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
40.7 M | 40.3 M | 40 M | 39.6 M | 39.3 M | 38.9 M | 19.4 M | 24 M | 28.5 M | 31.4 M | 31.2 M | 31.2 M | 25.2 M | 27.5 M | 30.6 M | 30.4 M | 30.2 M | 30 M | 29.8 M | 25.6 M | 18.9 M | 17 M | 11.9 M | 13.1 M | 15 M | 14.9 M | 14.8 M | 14.7 M | - | 14.7 M | 14.7 M | - | 10.1 M | 10 K | 8.71 M | 11.8 M | 9.91 M | 10.1 M | 10.1 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29 K | 283 K | - | 298 K | 111 K | 46 K | - | 37 K | 37 K | 37 K | - | - | - | - | - | - | - | - | - |
Total Liabilities |
57.3 M | 57.1 M | 64 M | 64.8 M | 65.4 M | 60.8 M | 56.1 M | 54 M | 50.8 M | 47.7 M | 49.3 M | 48.6 M | 47.7 M | 44.7 M | 45.2 M | 48.7 M | 48.3 M | 44.8 M | 42.3 M | 35.9 M | 33.6 M | 26.1 M | 19.5 M | 20.4 M | 20.7 M | 20.8 M | 18.9 M | 20 M | 5.36 M | 2.8 M | 8.13 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 286 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-499 M | -481 M | -460 M | -437 M | -412 M | -385 M | -363 M | -340 M | -319 M | -296 M | -277 M | -306 M | -288 M | -272 M | -257 M | -241 M | -225 M | -206 M | -188 M | -171 M | -155 M | -138 M | -128 M | -119 M | -108 M | -98.7 M | -87.6 M | -76.4 M | -63.6 M | -52.2 M | -39 M | -29.3 M | -186 M | -180 M | -163 M | -15.9 M | -135 M | -146 M | -146 M | -113 M | -113 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
55.7 M | 72.4 M | 99.2 M | 120 M | 144 M | 164 M | 153 M | 126 M | 140 M | 157 M | 176 M | 144 M | 141 M | 103 M | 88.4 M | 105 M | 120 M | 133 M | 93.1 M | 102 M | 67.4 M | 75.3 M | 34.2 M | 42.9 M | 33.3 M | 41.5 M | 49.8 M | 60.7 M | 57.4 M | 46.8 M | 61.9 M | 5.58 M | 38.2 M | 60 M | 73.2 M | 816 K | 96.9 M | 52.3 M | 58.6 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
27.5 M | 23 M | 15.2 M | 25.8 M | 26.3 M | 36.6 M | 46.6 M | 22.2 M | 49.3 M | 65.1 M | 108 M | 28.9 M | 52 M | 62.8 M | 22.6 M | 39.4 M | 19.4 M | 58.4 M | 63.4 M | 61.3 M | 16.9 M | 33.3 M | 33.2 M | 32 M | 13.1 M | 11.2 M | 14.5 M | 27.8 M | 56.3 M | 45.4 M | 61.2 M | 4.78 M | 37.1 M | 50 M | 50 M | 777 K | 14.4 M | 13.4 M | 53.9 M | 145 K | 7.9 M | 7.9 M | 7.9 M | 253 K | - | - | - | 468 K | - | - | - |
Book Value |
-1.6 M | 15.3 M | 35.2 M | 55.3 M | 78.3 M | 103 M | 97.3 M | 72.4 M | 89.5 M | 109 M | 126 M | 95 M | 93 M | 58.5 M | 43.2 M | 56.5 M | 71.7 M | 88.1 M | 50.8 M | 66.6 M | 33.8 M | 49.3 M | 14.7 M | 22.5 M | 12.6 M | 20.7 M | 30.9 M | 40.7 M | 52.1 M | 44 M | 53.7 M | -5.15 M | 27.5 M | 49.2 M | 62.5 M | 531 K | 96.9 M | 52.3 M | 58.6 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-1.6 M | 15.3 M | 35.2 M | 55.3 M | 78.3 M | 103 M | 97.3 M | 72.4 M | 89.5 M | 109 M | 126 M | 95 M | 93 M | 58.5 M | 43.2 M | 56.5 M | 71.7 M | 88.1 M | 50.8 M | 66.6 M | 33.8 M | 49.3 M | 14.7 M | 22.5 M | 12.6 M | 20.7 M | 30.9 M | 40.7 M | 52.1 M | 44 M | 53.7 M | -5.15 M | 36.4 M | 42.8 M | 58.1 M | 531 K | 82 M | 48.6 M | 54.6 M | 105 K | -51 M | -51 M | -51 M | 248 K | - | - | - | -71 M | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Eiger BioPharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
